{
    "nctId": "NCT00776308",
    "briefTitle": "Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery",
    "officialTitle": "Molecular Breast Imaging in the Preoperative Evaluation of Women With Biopsy Proven Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 98,
    "primaryOutcomeMeasure": "The gold standard for assessing MBI will be tissue pathology. Using pathology as the gold standard, we will compare the sensitivity of MBI to that of mammography in the evaluation of this patient population.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with biopsy-proven breast cancer (invasive breast cancer or ductal carcinoma in situ)\n\nExclusion Criteria:\n\n* Unable to understand and sign the consent form\n* Pregnant or lactating\n* Physically unable to sit upright and still for 40 minutes\n* Currently receiving neoadjuvant chemotherapy or hormonal therapy\n* Currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor\n* Previous mastectomy\n* Previous excisional biopsy of the index breast cancer",
    "sex": "FEMALE",
    "minimumAge": "25 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}